Drug or technology
48 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 5, 2026 · JOURNAL ARTICLE
Immunotherapy
This is a narrative review that raises questions and summarizes progress rather than reporting empirical results with effect sizes or comparative outcomes to answer them.
AUG 31, 2026 · JOURNAL ARTICLE
Research Journal of Biotechnology
This is a narrative review or commentary describing the concept and theoretical promise of tolerogenic vaccines without reporting original experimental data, efficacy results, or clinical outcomes.
AUG 26, 2026 · JOURNAL ARTICLE
Vaccine Insights
An expert interview on vaccine design principles and adjuvant strategy; informative for research direction but not empirical evidence of clinical efficacy or safety.
AUG 19, 2026 · JOURNAL ARTICLE
Journal of Medicine and Health Research
A critical narrative review synthesizing evidence across AI-genomics applications for infectious disease surveillance, identifying methodological gaps and recommending governance priorities rather than reporting new empirical results.
AUG 13, 2026 · JOURNAL ARTICLE
Experimental & Molecular Medicine
A narrative review synthesizing current evidence on personalized cancer vaccine development, proposing a framework for future optimization rather than reporting original empirical findings.
AUG 12, 2026 · REVIEW
Vaccines
A narrative review synthesizing the state of knowledge on personalized vaccine platforms for non-communicable diseases, offering a conceptual framework rather than original evidence of efficacy.
A narrative review summarizing neoantigen identification strategies and discussing challenges; raises questions about mechanistic pathways rather than reporting empirical results with effect sizes.
AUG 11, 2026 · JOURNAL ARTICLE
Communications Biology
Single-centre mechanistic study of three TCR constructs using multimodal profiling with in vivo tumour modelling; identifies functional hierarchy but lacks comparative efficacy statistics, power calculation, or clinical translation.